Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Ostrava - Moravska Ostrava, Czech Republic Clinical Trials

A listing of Ostrava - Moravska Ostrava, Czech Republic clinical trials actively recruiting patients volunteers.

RESULTS

Found (123) clinical trials

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis (1mg/mL Ciclosporin)

The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED) patients with severe keratitis receiving Ikervis (1mg/mL ciclosporin) eye drops administered once daily

Phase

5.08 miles

Learn More »

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. ...

Phase

5.43 miles

Learn More »

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide exposure, safety and efficacy data to identify the optimal regimen of PAN ...

Phase

5.43 miles

Learn More »

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

This is a randomized, double-blind, double-dummy, active comparator-controlled, parallel-group, multicenter study with variable treatment duration in approximately 900 patients with relapsing MS. The maximal treatment duration in the study for an individual patient will be 2.5 years. Eligible patients will be randomized to receive either experimental ofatumumab subcutaneous (sc) injections ...

Phase

5.43 miles

Learn More »

A Study of the Anti-PD1 Antibody PDR001 in Combination With Dabrafenib and Trametinib in Advanced Melanoma

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma

Phase

5.43 miles

Learn More »

To Evaluate the Safety and Efficacy of Remsima in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)

The primary objective of this study is to assess the safety of Remsima by evaluation of Events of Special Interest (ESI) in IBD patients, who have active Crohn's disease (CD), fistulizing Crohn's disease (CD), or Ulcerative Colitis (UC) for up to 5 years for each patient. The secondary objectives of ...

Phase N/A

5.43 miles

Learn More »

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderately to severely active Crohn's Disease (CD). The target population includes participants with CD who are refractory or intolerant to corticosteroids (CS) and/or immunosuppressant ...

Phase

5.43 miles

Learn More »

A Prospective Noninterventional Follow-Up Study of Children Aged 23 to 25 Months Born to Mothers Who Received Hydroxyprogesterone Caproate Injection 250 mg/mL or Vehicle for Prevention of Preterm Birth

This will be a prospective, noninterventional follow-up study designed to provide a developmental assessment of children born to mothers who participated in the 17P Efficacy Trial. When subjects reach an age of 23 months after adjustment for gestational age, they will be screened for developmental delay using the 24 month ...

Phase N/A

5.43 miles

Learn More »

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

This is an investigational study, also known as LATTICE-CD, of the experimental medication BMS-986165 in participants with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

Phase

5.43 miles

Learn More »

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

All subjects will receive a SC dose of either investigational product or placebo as the first dose on day 1. Subjects who are determined to be non-responders in Part A will receive tezepelumab SC Q2W following completion of all week 16 study activities. Nonresponders are defined as those subjects who ...

Phase

5.43 miles

Learn More »